| [1] |
中国健康促进基金会骨质疏松防治中国白皮书编委会.骨质疏松症中国白皮书[J].中华健康管理学杂志, 2009, 3(3): 148-154.
|
| [2] |
Cosman F,De Beur SJ,Leboff MS, et al. Clinician's guide to prevention and treatment of osteoporosis [J]. Osteoporos Int, 2014, 25(10): 2359-2381.
|
| [3] |
Rivadeneira F,Mäkitie O. Osteoporosis and bone mass disorders:from genepathwaystotreatments [J]. Trends Endocrinol Metab, 2016, 27(5): 262-281.
|
| [4] |
Seeman E,Delmas PD. Bone quality-thematerial and structural basis of bone strength and fragility [J]. N Engl J Med, 2008, 26(1): 1-8.
|
| [5] |
Mafi Golchin M,Heidari L,Ghaderian SM, et al. Osteoporosis: a silent disease with complex genetic contribution [J]. J Genetics Genomics, 2016, 43(2): 49-61.
|
| [6] |
Lewiecki EM. New targetsforintervention in the treatment of postmenopausal osteoporosis [J]. Nat Rev Rheumatol, 2011, 7(11): 631-638.
|
| [7] |
Balk EM,Adam GP,Langberg VN, et al. International osteoporosis foundation Calcium steering committee [J]. Global dietary calcium intake among adults:a systematic review[J].Osteoporos Int, 2017, 28(12): 3315-3324.
|
| [8] |
NordinBE. Calcium and osteoporosis [J]. Nutrition, 1997, 13(7/8): 664-686.
|
| [9] |
Wu J,Xu L,Lv Y, et al. Quantitative analysis of efficacy and associated factors of calcium intake on bone mineral density in postmenopausal women [J]. Osteoporos Int, 2017, 28(6): 2003-2010.
|
| [10] |
中华医学会骨质疏松和骨矿盐疾病学会.原发性骨质疏松症诊疗指南(2017) [J].中华骨质疏松和骨矿盐疾病杂志, 2017, 10(5): 413-444.
|
| [11] |
Dawson-Hughes B. What is the optimal dietary intake of vitamin D for reducing fracture risk? [J]. Calcif Tissue Int, 2013, 92(2):184-190.
|
| [12] |
Wahl DA,CooperC,EbelingPR, etal. A global representation of vitamin D status in healthy populations[J]. Arch Osteoporos, 2012, 7:155-172.
|
| [13] |
Li M,Lv F,Zhang Z, et al. Establishment of a normal reference value of parathyroid hormone in a large healthy Chinese population and evaluation of its relation to bone turnover and bone mineral density [J]. OsteoporosInt, 2016, 27(5): 1907-1916.
|
| [14] |
Holick MF. Vitamin D deficiency [J]. N Engl J Med, 2007, 357(3): 266-281.
|
| [15] |
Han SL,Wan SL. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials [J]. Int J Clin Pract, 2012, 66(2): 199-209.
|
| [16] |
Carmel AS,Shieh A,Bang H, et al. The 25(OH)D level needed to maintain a favorable bisphosphonate response is≥33 ng/ml [J]. Osteoporos Int, 2012, 23(10): 2479-2487.
|
| [17] |
Peris P,Martínez-Ferrer A,Monegal A, et al.25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis[J].Bone, 2012, 51(1): 54-58.
|
| [18] |
陈志军,邱勇.雌激素对骨骼作用机制的研究进展[J].中华创伤杂志, 2008, 24(4): 314-317.
|
| [19] |
WeitzmannMN,PacificiR. Estrogen deficiency and bone loss:aninflammatorytale [J]. JClinInvest, 2006, 116(5): 118.
|
| [20] |
易剑华,蒋志平.骨质疏松症的药物治疗进展[J].现代医院,2006,6(11): 55-56.
|
| [21] |
林华,包丽华,韩祖斌,等.降钙素治疗骨质疏松症骨质量病变的研究[J].中华骨科杂志, 2001, 21(9): 6-8.
|
| [22] |
李晓林,罗新乐,余楠生,等.鲑鱼降钙素对骨质疏松大鼠骨折愈合的影响[J].中国骨质疏松杂志, 2003, 9(2): 17-19, 53.
|
| [23] |
Lj X,Luo X,Yu N, et al. Effects of salmon calcitonin onfracture healing in ovariectomizedrats [J]. Saudi Med J, 2007, 28(1): 60-64.
|
| [24] |
Canalis E,Giustina A,Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis [J]. N Engl J Med, 2007, 357(9): 905-916.
|
| [25] |
Bukata SV,Puzas JE. Orthopedic uses of teriparatide [J]. CurrOsteoporos Rep, 2010, 8(1): 28-33.
|
| [26] |
NakajimaA,ShimojiN,ShiomiK,et a1.Mechanisms for theenhancement of fracture healing in ratstreated with intermittentlow-dosehumanparathyroidhormone(1-34)[J].JBone MinerRes,2002,17(11):2038-2047．
|
| [27] |
Taranta A,Brama M,Teti A, et al. The selective estrogenreceptormodulatorraloxifeneregulates osteoclast and osteoblast activity in vitro [J]. Bone, 2002, 30(2): 368-376.
|
| [28] |
刘立朝,樊继援.雷洛昔芬对去卵巢大鼠骨组织雌激素受体α表达水平的调节[J].中华骨质疏松和骨矿盐疾病杂志, 2013, 6(2): 161-164.
|
| [29] |
廖晖,李锋.二磷酸盐抑制骨吸收作用机制的研究现状[J].生物骨科材料与临床研究, 2004, 1(2): 20-24.
|
| [30] |
Abe Y,Iba K,Sasaki K, et al. Inhibitory effect of bisphosphonate on osteoclast function contributes to improved skeletal pain in ovariectomized mice [J]. J Bone Miner Metab, 2015, 33(2): 125-134.
|
| [31] |
FleischH.Canbisphosphonates be given to patients with fractures? [J].JBoneMinerRes, 2001, 16(3): 437-440.
|
| [32] |
Schilcher J,Koeppen V,Aspenberg P, et al. Risk of atypical femoral fracture during and after bisphosphonate use [J]. N Engl J Med, 2014, 371(10): 974-976.
|
| [33] |
Moen MD,Keam SJ. Denosumab: areview of itsuse in thetreatment of postmenopausalosteoporosis[J].DrugsAging, 2011, 28(1): 63-82.
|
| [34] |
Mcclung MR,Boonen ST，Rring O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis[J]. Journal of bone and mineral research，2012, 27(1):211-218.
|
| [35] |
Nikhil K,Sharan S,Roy P. A pterostilbene derivative suppresses osteoclastogenesis by regulating RANKL-mediated NFκB and MAPK signaling in RAW264.7 cells[J]. Pharmacological Reports, 2015, 67(6):1264-1272.
|
| [36] |
Ke HZ,Richards WG,Li XD, et al. Sclerostin and dickkopf-1 as therapeutic targets in bone diseases [J]. Endocr Rev, 2012, 33(5): 747-783.
|